The Contribution of Inherited Thrombophilia to Venous Thromboembolism in Cancer Patients.

IF 2.3 4区医学 Q2 HEMATOLOGY

Clinical and Applied Thrombosis/Hemostasis Pub Date : 2024-01-01 DOI:10.1177/10760296241232864

José Costa, António Araújo

{"title":"The Contribution of Inherited Thrombophilia to Venous Thromboembolism in Cancer Patients.","authors":"José Costa, António Araújo","doi":"10.1177/10760296241232864","DOIUrl":null,"url":null,"abstract":"<p><p>Although the relationship between venous thromboembolism (VTE) and cancer has been a subject of study, knowledge of the contribution of thrombophilia to thrombosis in patients with cancer is still very limited. The aim of this article is to collect present knowledge on the contribution of inherited thrombophilia to VTE in cancer patients. We performed a search in Google Scholar and PubMed and selected 21 from 76 returned articles. Then we made a narrative review of the selected articles. We describe 11 studies on the contribution of inherited thrombophilia to VTE in cancer patients in general and 10 on that contribution in specific types of cancer: 1 in colorectal cancer, 4 in breast cancer, 1 in gynecologic cancer and 4 in hematopoietic malignancies. All studies investigate the relation of factor V Leiden (FVL) to VTE, 13 that of the prothrombin G20210A mutation (PTG20210A) and 7 studies also investigate other inherited thrombophilias, such methylenetetrahydrofolate reductase gene mutations, although only 2 investigate the contribution of deficiencies of the natural anticoagulants. Studies are very heterogeneous, in design and sample size and conclusions differ considerably. There is no consensus on the contribution of inherited thrombophilia to VTE in cancer patients except for acute lymphoblastic leukemia in children. Probably, that contribution is not the same for all types of cancer and more studies are needed to bring more knowledge on this subject.</p>","PeriodicalId":10335,"journal":{"name":"Clinical and Applied Thrombosis/Hemostasis","volume":"30 ","pages":"10760296241232864"},"PeriodicalIF":2.3000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10916497/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Applied Thrombosis/Hemostasis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/10760296241232864","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Although the relationship between venous thromboembolism (VTE) and cancer has been a subject of study, knowledge of the contribution of thrombophilia to thrombosis in patients with cancer is still very limited. The aim of this article is to collect present knowledge on the contribution of inherited thrombophilia to VTE in cancer patients. We performed a search in Google Scholar and PubMed and selected 21 from 76 returned articles. Then we made a narrative review of the selected articles. We describe 11 studies on the contribution of inherited thrombophilia to VTE in cancer patients in general and 10 on that contribution in specific types of cancer: 1 in colorectal cancer, 4 in breast cancer, 1 in gynecologic cancer and 4 in hematopoietic malignancies. All studies investigate the relation of factor V Leiden (FVL) to VTE, 13 that of the prothrombin G20210A mutation (PTG20210A) and 7 studies also investigate other inherited thrombophilias, such methylenetetrahydrofolate reductase gene mutations, although only 2 investigate the contribution of deficiencies of the natural anticoagulants. Studies are very heterogeneous, in design and sample size and conclusions differ considerably. There is no consensus on the contribution of inherited thrombophilia to VTE in cancer patients except for acute lymphoblastic leukemia in children. Probably, that contribution is not the same for all types of cancer and more studies are needed to bring more knowledge on this subject.

查看原文本刊更多论文

遗传性血栓性疾病对癌症患者静脉血栓栓塞症的影响。

尽管静脉血栓栓塞症（VTE）与癌症之间的关系一直是研究的主题，但有关血栓性疾病对癌症患者血栓形成的影响的知识仍然非常有限。本文旨在收集有关遗传性血栓性疾病导致癌症患者 VTE 的现有知识。我们在 Google Scholar 和 PubMed 上进行了搜索，从 76 篇检索到的文章中筛选出 21 篇。然后，我们对所选文章进行了叙述性综述。我们介绍了 11 项关于遗传性血栓性疾病导致癌症患者 VTE 的研究，以及 10 项关于遗传性血栓性疾病导致特定类型癌症患者 VTE 的研究：1 项研究涉及结直肠癌，4 项研究涉及乳腺癌，1 项研究涉及妇科癌症，4 项研究涉及造血恶性肿瘤。所有研究都调查了因子 V Leiden（FVL）与 VTE 的关系，13 项研究调查了凝血酶原 G20210A 突变（PTG20210A）与 VTE 的关系，7 项研究还调查了其他遗传性血栓性疾病，如亚甲基四氢叶酸还原酶基因突变，但只有 2 项研究调查了天然抗凝剂缺陷的影响。这些研究在设计和样本量上都存在很大差异，结论也大相径庭。除儿童急性淋巴细胞白血病外，遗传性血栓性疾病对癌症患者 VTE 的影响尚未达成共识。可能所有类型的癌症对 VTE 的影响都不尽相同，因此需要进行更多的研究来加深对这一问题的认识。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical and Applied Thrombosis/Hemostasis 医学-外周血管病

CiteScore

4.40

自引率

3.40%

发文量

150

审稿时长

2 months

期刊介绍： CATH is a peer-reviewed bi-monthly journal that addresses the practical clinical and laboratory issues involved in managing bleeding and clotting disorders, especially those related to thrombosis, hemostasis, and vascular disorders. CATH covers clinical trials, studies on etiology, pathophysiology, diagnosis and treatment of thrombohemorrhagic disorders.